文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

电机械优化右心室起搏治疗梗阻性肥厚型心肌病:EMORI-HCM试验

Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy: The EMORI-HCM Trial.
PubMed 文献 · J Am Coll Cardiol · 2025-08-31

EMORI-HCM是一项多中心、盲法、随机交叉试验,纳入60例有症状的梗阻性肥厚型心肌病患者(静息或激发后左室流出道压差≥30 mmHg),比较电机械优化房室延迟的右心室起搏与备用起搏。结果显示优化起搏改善堪萨斯城心肌病问卷临床汇总评分(+4.5;95%CrI 1.3-8.1;获益概率0.997)、每日症状评分、运动能力和左室流出道压差,且不降低射血分数。

要点

  • 电机械优化房室延迟的右心室起搏可改善有症状oHCM患者的症状和运动能力
  • 优化起搏使KCCQ临床汇总评分提高4.5分(95%CrI 1.3-8.1),获益概率0.997
  • 优化起搏降低左室流出道压差7.3 mmHg,且射血分数保持稳定

核心结论

  • 在有症状的梗阻性肥厚型心肌病患者中,以电机械优化房室延迟进行的右心室起搏可改善症状和运动能力。

研究设计与样本

  • EMORI-HCM为多中心、盲法、随机交叉试验,纳入静息或激发后左室流出道压差≥30 mmHg的有症状梗阻性肥厚型心肌病患者,共60例随机。
  • 患者随机接受3个月连续电机械优化房室延迟的右心室起搏(干预)后3个月备用起搏(对照),或相反顺序。
  • 房室延迟通过高精度多次交替协议优化,评估逐搏血压的急性变化。

主要发现

  • 与备用起搏相比,优化起搏改善堪萨斯城心肌病问卷临床汇总评分(+4.5;95%CrI 1.3-8.1;获益概率0.997)。
  • 优化起搏改善每日症状评分(OR 1.29;95%CrI 0.98-1.68;获益概率0.969)。
  • 优化起搏改善运动能力(+1.0 mL/kg/min;95%CrI 0.1-2.0;获益概率0.984)。
  • 优化起搏降低左室流出道压差(-7.3 mmHg;95%CrI -13.5至-1.1;获益概率0.010)。
  • 优化起搏对B型利钠肽无效应(获益概率0.893),射血分数保持稳定(获益概率0.409)。

临床怎么用

  • 对于已植入双腔装置的有症状梗阻性肥厚型心肌病患者,可考虑采用电机械优化房室延迟的右心室起搏以改善症状和运动能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) have devices capable of right ventricular pacing (RVP). Although pacing can reduce left ventricular outflow tract gradient (LVOTg), it can also reduce cardiac output, so its net effect is variable. OBJECTIVES: We tested whether electromechanical optimization of the programmed atrio-ventricular delay (AVD) allows RVP to achieve a net benefit on symptoms. METHODS: EMORI-HCM (Electromechanically Optimized Right Ventricular Pacing in Obstructive Hypertrophic Cardiomyopathy) is a multicenter, blinded, randomized, crossover trial of AVD-optimized RVP in patients with symptomatic oHCM with resting or provoked gradient of at least 30 mm Hg. Patients with existing dual-chamber devices were randomized to either 3 months of continuous AVD-optimized RVP (intervention) followed by 3 months of backup-only RVP (control), or vice versa. AVD was optimized using a high-precision multiple-alternation protocol assessing acute change in beat-by-beat blood pressure while varying AVD. The primary outcome was symptoms measured by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score. Secondary outcomes include patient-reported daily symptom data collected using a dedicated smartphone application (ORBITA-app), dichotomous patient preference, EQ-5D, exercise capacity, and LVOTg. Patients were blinded to treatment allocation. Symptom assessments were self-administered. Outcome measures were recorded at baseline, crossover, and completion. Analysis was by Bayesian ordinal mixed modeling. RESULTS: Between October 2021 and October 2024, 117 screened patients met the inclusion criteria, of whom 60 were randomized. AVD-optimized RVP improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (+4.5; 95% credible interval [CrI]: 1.3-8.1; probability of benefit [Prbenefit] = 0.997) and daily symptom scores (OR: 1.29; 95% CrI: 0.98-1.68; Prbenefit: 0.969) compared with backup-only pacing. AVD-optimized RVP improved exercise capacity (+1.0 mL/kg/min; 95% CrI: 0.1-2.0; Prbenefit: 0.984) and LVOTg (-7.3 mm Hg; 95% CrI: -13.5 to -1.1; Prbenefit: 0.010). It had no effect on B-type natriuretic peptide (Prbenefit: 0.893) and ejection fraction was preserved (Prbenefit: 0.409). CONCLUSIONS: In patients with oHCM, RVP delivered at electromechanically optimized AVD improves symptoms and exercise capacity. (Electromechanically Optimized Right Ventricular Pacing in Obstructive Hypertrophic Cardiomyopathy [EMORI-HCM], NCT05257772).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Mohal JS, Whinnett ZI, Mohiddin SA, et al. Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy: The EMORI-HCM Trial. J Am Coll Cardiol. 2025. PMID: 40892619. doi:10.1016/j.jacc.2025.08.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。